Does Omega-3 supplementation after the age of 65 influence cognitive function? Results of a systematic review
DOI:
https://doi.org/10.23938/ASSN.0046Keywords:
Fatty Acids. Omega-3. Cognitive Impairment. Dementia. Aging.Abstract
Background. The percentage of the older population is progressively increasing as are diseases associated with aging such as cognitive decline (CD) and dementia. Observational epidemiological studies suggest that diets rich in omega 3 polyunsaturated fatty acids (w3-PUFA) might reduce the risk of CD and dementia. The main objective was to assess whether there is sufficient scientific evidence about the relationship between w3-PUFA supplementation in patients aged 65 or older and cognitive performance.
Methods. We used the Pubmed data base to search for articles related to w3-PUFA and CD or dementia. Initially we identified 582 articles, after applying the eligibility criterion we included six studies in this systematic review.
Results. The studies included were heterogeneous regarding population, measurement of exposure and outcome. Therefore, it was not possible to conduct a quantitative analysis. Two studies found that w3-PUFA supplementation decreased the risk of Alzheimer and improved cognitive performance. Two studies found an improvement in only one of the domains of cognitive performance (visual analogical classification and verbal fluency) and another two did not find any evidence of protection.
Conclusions. We found few studies to support or refute the evidence that w3-PUFA supplementation in patients aged 65 or older improves cognitive performance or prevents dementia.
Downloads
References
ORGANIZACIÓN MUNDIAL DE LA SALUD. Demencia. http://www.who.int/mediacentre/factsheets/fs362/es/. Consultado el 4 de febrero de 2017.
CASAS HERRERO A, IZQUIERDO M. Ejercicio físico como intervención eficaz en el anciano frágil. An Sist Sanit Navar 2012; 35: 69-85.
FRANCÉS I, BARANDIARÁN M, MARCELLÁN T, MORENO L. Psychocognitive stimulation in dementias. An Sist Sanit Navar 2003; 26: 383-403.
MARTÍN-CALVO N, MORENO-GALARRAGA L, BES-RASTROLLO M. La importancia de la nutrición y los estilos de vida saludables en la infancia y adolescencia. An Sist Sanit Navar 2015; 38: 461-462.
WAITZBERG DL, GARLA P. Contribución de los ácidos grasos omega-3 para la memoria y la función cognitiva. Nutr Hosp 2014; 30: 467-477.
HERNÁNDEZ RUIZ DE EGUILAZ M, BATLLE MA, MARTÍNEZ DE MORENTIN B, SAN-CRISTÓBAL R, PÉREZ-DÍEZ S, NAVAS-CARRETERO S et al. Cambios alimentarios y de estilo de vida como estrategia en la prevención del síndrome metabólico y la diabetes mellitus tipo 2: hitos y perspectivas. An Sist Sanit Navar 2016; 39: 269-289.
YANAI H. Effects of N-3 Polyunsaturated fatty acids on dementia. J Clin Med Res 2017; 9: 1-9.
ZHANG X-W, HOU W-S, LI M, TANG Z-Y. Omega-3 fatty acids and risk of cognitive decline in the elderly: a meta-analysis of randomized controlled trials. Aging Clin Exp Res 2016; 28: 165-166.
ZHANG Y, CHEN J, QIU J, LI Y, WANG J, JIAO J. Intakes of fish and polyunsaturated fatty acids and mild-to-severe cognitive impairment risks: a dose-response meta-analysis of 21 cohort studies. Am J Clin Nutr 2016; 103: 330-340.
ABUBAKARI A-R, NADERALI M-M, NADERALI EK. Omega-3 fatty acid supplementation and cognitive function: are smaller dosages more beneficial? Int J Gen Med 2014; 7: 463-473.
YURKO-MAURO K, ALEXANDER DD, VAN ELSWYK ME. Docosahexaenoic acid and adult memory: a systematic review and meta-analysis. PLoS One 2015; 10: e0120391. doi: 10.1371/journal.pone.0120391
BURCKHARDT M, HERKE M, WUSTMANN T, WATZKE S, LANGER G, FINKA. Omega-3 fatty acids for the treatment of dementia. Cochrane Database of Systematic Reviews 2012, Issue 4. doi:10.1002/14651858.CD009002.pub3
SYDENHAM E, DANGOUR AD, LIM WS. Omega fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews 2012, Issue 6. doi: 10.1002/14651858.CD005379.pub3
JIAO J, LI Q, CHU J, ZENG W, YANG M, ZHU S. Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014; 100: 1422-1436.
CHIU CC, SU KP, CHENG TC, LIU HC, CHANG CJ, DEWEY ME et al. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1538-1544.
MAZEREEUW G, LANCTÔT KL, CHAU SA, SWARDFAGER W, HERRMANN N. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol Aging 2012; 33: 1482.e17-1482.e29.
LIBERATI A, ALTMAN DG, TETZLAFF J, MULROW C, GØTZSCHE PC, IOANNIDIS JPA et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700. doi: 10.1136/bmj.b2700
WALLACE BC, SMALL K, BRODLEY CE, LAU J, TRIKALINOS TA. Deploying an interactive machine learning system in an evidence-based practice center Abstrackr. En: Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium. New York: ACM Press 2012: 819-824.
BUN S, IKEJIMA C, KIDA J, YOSHIMURA A, LEBOWITZ AJ, KAKUMA T et al. A combination of supplements may reduce the risk of alzheimer’s disease in elderly japanese with normal cognition. J Alzheimer’s Dis 2015; 45: 15-25.
RONDANELLI M, OPIZZI A, FALIVA M, MOZZONI M, ANTONIELLO N, CAZZOLA R et al. Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment. Nutr Neurosci 2012; 15: 46-54.
BOSTON PF, BENNETT A, HORROBIN DF, BENNETT CN. Ethyl-EPA in Alzheimer’s disease—a pilot study. Prostaglandins Leukot Essent Fatty Acids 2004; 7: 341-346.
DANGOUR AD, ALLEN E, ELBOURNE D, FASEY N, FLETCHER AE, HARDY P et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial. Am J Clin Nutr 2010; 91: 1725-1732.
VAN DE REST O, GELEIJNSE JM, KOK FJ, VAN STAVEREN WA, DULLEMEIJER C, OLDERIKKERT MGM, et al. Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 2008; 71: 430-438.
SINN N, MILTE CM, STREET SJ, BUCKLEY JD, COATES AM, PETKOV J, et al. Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr 2012; 107: 1682-1693
DYERBERG J, MADSEN P, MØLLER JM, AARDESTRUP I, SCHMIDT EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids 2010; 83: 137-141.
BARBERGER-GATEAU P. Nutrition and brain aging: how can we move ahead? Eur J Clin Nutr 2014; 68: 1245-1249.
STRIKE SC, CARLISLE A, GIBSON EL, DYALL SC. A high omega-3 fatty acid multinutrient supplement benefits cognition and mobility in older women: a randomized, double-blind, placebo-controlled pilot study. J Gerontol A Biol Sci Med Sci 2016; 71: 236-242.
GELEIJNSE JM, GILTAY EJ, KROMHOUT D. Effects of n-3 fatty acids on cognitive decline: A randomized, double-blind, placebo-controlled trial in stable myocardial infarction patients. Alzheimer’s Dement 2012; 8: 278-287.
Organización Mundial de la Salud. La esperanza de vida ha aumentado en 5 años desde el año 2000, pero persisten las desigualdades sanitarias. http://www.who.int/mediacentre/news/releases/2016/health-inequalities-persist/es/. Consultado el 9 de junio de 2017.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
